MA38960A1 - Formulations d'anticorps anti-pdl1 - Google Patents
Formulations d'anticorps anti-pdl1Info
- Publication number
- MA38960A1 MA38960A1 MA38960A MA38960A MA38960A1 MA 38960 A1 MA38960 A1 MA 38960A1 MA 38960 A MA38960 A MA 38960A MA 38960 A MA38960 A MA 38960A MA 38960 A1 MA38960 A1 MA 38960A1
- Authority
- MA
- Morocco
- Prior art keywords
- pdl1 antibody
- antibody formulations
- formulations
- methods
- pdl1
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361883953P | 2013-09-27 | 2013-09-27 | |
| PCT/US2014/057821 WO2015048520A1 (en) | 2013-09-27 | 2014-09-26 | Anti-pdl1 antibody formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA38960A1 true MA38960A1 (fr) | 2017-10-31 |
Family
ID=51703416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38960A MA38960A1 (fr) | 2013-09-27 | 2014-09-26 | Formulations d'anticorps anti-pdl1 |
Country Status (32)
Families Citing this family (126)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202442680A (zh) | 2008-12-09 | 2024-11-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| EP2707030B1 (en) | 2011-05-09 | 2020-02-19 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| WO2014055415A1 (en) | 2012-10-01 | 2014-04-10 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| EP4285928A3 (en) | 2013-09-27 | 2024-03-13 | F. Hoffmann-La Roche AG | Anti-pdl1 antibody formulations |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| AU2015274408A1 (en) | 2014-06-13 | 2017-01-12 | Mayo Foundation For Medical Education And Research | Treating lymphomas |
| EA201692502A1 (ru) | 2014-06-16 | 2017-09-29 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Лечение миелом |
| JP6681905B2 (ja) | 2014-09-13 | 2020-04-15 | ノバルティス アーゲー | Ａｌｋ阻害剤の併用療法 |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| EA201790834A1 (ru) | 2014-10-14 | 2018-01-31 | Новартис Аг | Молекулы антител к pd-l1 и их применение |
| IL292449B2 (en) | 2015-03-13 | 2024-02-01 | Cytomx Therapeutics Inc | Nucleic acids encoding anti-pdl1 antibodie and methods of producing same |
| CA3025145A1 (en) * | 2015-05-22 | 2016-12-01 | Translational Drug Development Llc | Benzamide and active compound compositions and methods of use |
| CN108289953B (zh) | 2015-09-29 | 2022-03-11 | 细胞基因公司 | Pd-1结合蛋白及其使用方法 |
| EP3356551B1 (en) | 2015-09-29 | 2020-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for determining the metabolic status of b-lymphomas |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| CA3004804A1 (en) | 2015-11-17 | 2017-05-26 | Jiangsu Hengrui Medicine Co., Ltd. | Pd-l1 antibody, antigen-binding fragment thereof and medical application thereof |
| BR112018010211A2 (pt) | 2015-12-07 | 2019-02-05 | Merck Patent Gmbh | formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab |
| PT3394103T (pt) | 2015-12-22 | 2023-09-04 | Regeneron Pharma | Combinação de anticorpos anti-pd-1 e anticorpos biespecíj'icos anti-cd20/anti-cd3 para tratar cancro |
| EP3400443B1 (en) | 2016-01-04 | 2020-09-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma |
| WO2017120501A1 (en) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon |
| KR20180097615A (ko) | 2016-01-08 | 2018-08-31 | 에프. 호프만-라 로슈 아게 | Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법 |
| CA3014531A1 (en) | 2016-02-12 | 2017-08-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| CN109153719B (zh) | 2016-03-15 | 2022-12-30 | 中外制药株式会社 | 使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法 |
| US11878061B2 (en) | 2016-03-21 | 2024-01-23 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
| CA3018341A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| TWI755395B (zh) | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
| US10077308B2 (en) | 2016-06-13 | 2018-09-18 | Askgene Pharma Inc. | PD-L1 specific monoclonal antibodies for disease treatment and diagnosis |
| CN115998859A (zh) | 2016-06-27 | 2023-04-25 | 莫佛塞斯公司 | 抗-cd19抗体制剂 |
| WO2018027524A1 (en) * | 2016-08-09 | 2018-02-15 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibody formulation |
| CN106977602B (zh) | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
| CN106967172B (zh) | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| KR102462041B1 (ko) | 2016-09-01 | 2022-11-02 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물 |
| CN109843336A (zh) | 2016-09-01 | 2019-06-04 | 梅约医学教育与研究基金会 | 用于靶向t细胞癌症的方法和组合物 |
| EP3509635A1 (en) | 2016-09-06 | 2019-07-17 | Vavotar Life Sciences LLC | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| CN109843924A (zh) | 2016-09-06 | 2019-06-04 | 梅约医学教育与研究基金会 | 治疗表达pd-l1的癌症的方法 |
| JP7025412B2 (ja) | 2016-09-06 | 2022-02-24 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | パクリタキセル－アルブミン－結合剤組成物並びに該組成物の使用及び製造方法 |
| US10766958B2 (en) | 2016-09-19 | 2020-09-08 | Celgene Corporation | Methods of treating vitiligo using PD-1 binding antibodies |
| BR112019004733A2 (pt) | 2016-09-19 | 2019-05-28 | Celgene Corp | métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1 |
| KR20190125363A (ko) * | 2017-03-06 | 2019-11-06 | 메르크 파텐트 게엠베하 | 수성 항-pd-l1 항체 제제 |
| US20210186982A1 (en) | 2017-03-24 | 2021-06-24 | Universite Nice Sophia Antipolis | Methods and compositions for treating melanoma |
| MX2019010999A (es) * | 2017-03-29 | 2020-02-05 | Celgene Corp | Formulaciones que comprenden proteinas de union a pd-1 y metodos para preparar las mismas. |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| EP3624846B1 (en) | 2017-05-16 | 2024-08-07 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity including a combination of nicotinic acid and tryoptophan |
| JP7263256B6 (ja) * | 2017-05-16 | 2023-07-24 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | Ｐｄ－ｌ１抗体医薬組成物およびその使用 |
| JP2020522486A (ja) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| CN107384870A (zh) * | 2017-07-31 | 2017-11-24 | 时力生物科技（北京）有限公司 | 一种靶向pd‑l1嵌合抗原受体修饰的t淋巴细胞及其制备方法和应用 |
| WO2019032663A1 (en) * | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | PD-1 AND PD-L1 BINDING AGENTS |
| US20200216542A1 (en) * | 2017-09-20 | 2020-07-09 | Chugai Seiyaku Kabushiki Kaisha | Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent |
| CN114632150B (zh) * | 2017-11-02 | 2023-12-19 | 正大天晴药业集团股份有限公司 | 一种抗pd-l1人源化单克隆抗体的药物组合物 |
| EP3735590A1 (en) | 2018-01-04 | 2020-11-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma resistant |
| CA3087105A1 (en) | 2018-01-10 | 2019-07-18 | Jiangsu Hengrui Medicine Co., Ltd. | Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
| EP3756012A1 (en) | 2018-02-21 | 2020-12-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors |
| IL277095B2 (en) * | 2018-03-07 | 2025-10-01 | Pfizer | Preparations containing anti-PD-1 antibody |
| US12331068B2 (en) | 2018-05-31 | 2025-06-17 | Peloton Therapeutics, Inc. | Compositions and methods for inhibiting CD73 |
| KR20210056288A (ko) * | 2018-06-01 | 2021-05-18 | 타유 후아시아 바이오테크 메디컬 그룹 컴퍼니 리미티드 | 질환 또는 병태를 치료하기 위한 조성물 및 그의 용도 |
| WO2019227490A1 (en) | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
| WO2020007817A1 (en) * | 2018-07-04 | 2020-01-09 | F. Hoffmann-La Roche Ag | Novel bispecific agonistic 4-1bb antigen binding molecules |
| CN112955221A (zh) | 2018-08-27 | 2021-06-11 | 皮里斯制药有限公司 | 包含cd137/her2双特异性试剂和pd-1轴抑制剂的组合疗法及其用途 |
| WO2020094744A1 (en) * | 2018-11-06 | 2020-05-14 | Genmab A/S | Antibody formulation |
| EP3883964A1 (en) | 2018-11-20 | 2021-09-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Bispecific antibody targeting transferrin receptor 1 and soluble antigen |
| WO2020104479A1 (en) | 2018-11-20 | 2020-05-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies |
| WO2020108497A1 (zh) * | 2018-11-29 | 2020-06-04 | 和铂医药（香港）有限公司 | 一种抗pd-l1抗体制剂 |
| TW202034951A (zh) | 2018-12-07 | 2020-10-01 | 日商小野藥品工業股份有限公司 | 免疫抑制劑 |
| WO2020115261A1 (en) | 2018-12-07 | 2020-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| MA54448A (fr) | 2018-12-11 | 2021-10-20 | Theravance Biopharma R&D Ip Llc | Dérivés naphthyridine et quinoléine en tant qu'inhibiteurs de alk5 |
| WO2020120592A1 (en) | 2018-12-12 | 2020-06-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for predicting and treating melanoma |
| WO2020127411A1 (en) | 2018-12-19 | 2020-06-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d |
| WO2020127885A1 (en) | 2018-12-21 | 2020-06-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions for treating cancers and resistant cancers |
| WO2020151572A1 (en) | 2019-01-23 | 2020-07-30 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Anti-pd-l1 diabodies and the use thereof |
| JP7442536B2 (ja) | 2019-01-30 | 2024-03-04 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ガンを患っている被験体が免疫チェックポイント阻害剤で反応を達成するかを特定するための方法及び組成物 |
| WO2020161083A1 (en) | 2019-02-04 | 2020-08-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for modulating blood-brain barrier |
| WO2020165370A1 (en) | 2019-02-13 | 2020-08-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for selecting a cancer treatment in a subject suffering from cancer |
| MA55033A (fr) | 2019-02-18 | 2021-12-29 | Lilly Co Eli | Formulation d'anticorps thérapeutique |
| CN109929037B (zh) | 2019-04-01 | 2023-03-17 | 华博生物医药技术（上海）有限公司 | 针对程序性死亡配体的结合物及其应用 |
| EP3963109A1 (en) | 2019-04-30 | 2022-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| KR20220034169A (ko) * | 2019-07-10 | 2022-03-17 | 리제너론 파아마슈티컬스, 인크. | 감소된 수준의 숙주 세포 단백질을 포함하는 방법 및 조성물 |
| WO2021048292A1 (en) | 2019-09-11 | 2021-03-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| US20220354811A1 (en) | 2019-10-03 | 2022-11-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for modulating macrophages polarization |
| CA3157889A1 (en) | 2019-10-17 | 2021-04-22 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for diagnosing nasal intestinal type adenocarcinomas |
| JP7450710B2 (ja) | 2019-10-21 | 2024-03-15 | 上▲海▼宏成▲薬▼▲業▼有限公司 | 抗ｐｄ－ｌ１抗体及びその製薬用途 |
| US20240122938A1 (en) | 2019-10-29 | 2024-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating uveal melanoma |
| CA3160307A1 (en) | 2019-11-22 | 2021-05-27 | Theravance Biopharma R&D Ip, Llc | Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors |
| AU2020399619A1 (en) * | 2019-12-09 | 2022-06-09 | Genentech, Inc. | Anti-PD-L1 antibody formulations |
| WO2021123243A1 (en) | 2019-12-19 | 2021-06-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and vaccine compositions to treat cancers |
| EP4090770A1 (en) | 2020-01-17 | 2022-11-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| US20230072528A1 (en) | 2020-02-05 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki) |
| EP4110955A1 (en) | 2020-02-28 | 2023-01-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing, prognosing and managing treatment of breast cancer |
| WO2021203131A1 (en) | 2020-03-31 | 2021-10-07 | Theravance Biopharma R&D Ip, Llc | Substituted pyrimidines and methods of use |
| TW202214623A (zh) | 2020-06-10 | 2022-04-16 | 美商施萬生物製藥研發 Ip有限責任公司 | 結晶型alk5抑制劑及其用途 |
| WO2022023379A1 (en) | 2020-07-28 | 2022-02-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for preventing and treating a cancer |
| US11865082B2 (en) | 2020-09-09 | 2024-01-09 | Hoffmann-La Roche Inc. | Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1 |
| WO2022084531A1 (en) | 2020-10-23 | 2022-04-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating glioma |
| EP4244392A1 (en) | 2020-11-16 | 2023-09-20 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for predicting and treating uveal melanoma |
| US20230416830A1 (en) | 2020-11-16 | 2023-12-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for predicting and treating uveal melanoma |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| WO2022194908A1 (en) | 2021-03-17 | 2022-09-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| EP4326903A1 (en) | 2021-04-23 | 2024-02-28 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating cell senescence accumulation related disease |
| WO2022251359A1 (en) | 2021-05-26 | 2022-12-01 | Theravance Biopharma R&D Ip, Llc | Bicyclic inhibitors of alk5 and methods of use |
| JP2024544358A (ja) * | 2021-10-29 | 2024-11-29 | ナセント バイオテック インコーポレイテッド | ビメンチンを発現する腫瘍を治療するためのキットおよび容器 |
| WO2023078900A1 (en) | 2021-11-03 | 2023-05-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating triple negative breast cancer (tnbc) |
| KR20240111310A (ko) * | 2021-12-08 | 2024-07-16 | 훼링 비.브이. | 단백질 정제 방법 |
| US20250041261A1 (en) | 2021-12-21 | 2025-02-06 | Institut National de la Santé et de la Recherche Médicale | Methods and compositions for treating melanoma |
| WO2024033399A1 (en) | 2022-08-10 | 2024-02-15 | Institut National de la Santé et de la Recherche Médicale | Sigmar1 ligand for the treatment of pancreatic cancer |
| WO2024033400A1 (en) | 2022-08-10 | 2024-02-15 | Institut National de la Santé et de la Recherche Médicale | Sk2 inhibitor for the treatment of pancreatic cancer |
| WO2024056716A1 (en) | 2022-09-14 | 2024-03-21 | Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy |
| WO2024084034A1 (en) | 2022-10-21 | 2024-04-25 | Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for the treatment of osteoarthritis |
| WO2024126750A1 (en) | 2022-12-15 | 2024-06-20 | F. Hoffmann-La Roche Ag | Methods for treating cancer |
| WO2024192108A1 (en) | 2023-03-14 | 2024-09-19 | Evolveimmune Therapeutics, Inc. | Genetically modified car t cells and methods of making and using the same |
| WO2024200571A1 (en) | 2023-03-28 | 2024-10-03 | Institut National de la Santé et de la Recherche Médicale | Method for discriminating mono-immunotherapy from combined immunotherapy in cancers |
| WO2024231384A1 (en) | 2023-05-10 | 2024-11-14 | Institut National de la Santé et de la Recherche Médicale | Compositions for treating senescence related disease |
| WO2024245951A1 (en) | 2023-05-26 | 2024-12-05 | Institut National de la Santé et de la Recherche Médicale | Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma |
| WO2024256635A1 (en) | 2023-06-15 | 2024-12-19 | Institut National de la Santé et de la Recherche Médicale | Dpm1 inhibitor for treating cancer |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
| WO2025078632A1 (en) | 2023-10-12 | 2025-04-17 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from cancer |
| WO2025132479A1 (en) | 2023-12-18 | 2025-06-26 | Institut National de la Santé et de la Recherche Médicale | Flt3 inhibitor for modulating macrophages polarization |
| WO2025132770A1 (en) | 2023-12-22 | 2025-06-26 | Institut National de la Santé et de la Recherche Médicale | Affitins for the treatment of cancer |
| WO2025210123A1 (en) | 2024-04-03 | 2025-10-09 | Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for treating cancers |
| WO2025219330A1 (en) | 2024-04-15 | 2025-10-23 | Institut National de la Santé et de la Recherche Médicale | Detection of ppix for use in methods for melanoma ferroptosis sensitivity and targeted therapy resistance prediction |
| WO2025228998A1 (en) | 2024-04-30 | 2025-11-06 | Institut National de la Santé et de la Recherche Médicale | Use of hdac4 inhibitors for the treatment of melanoma |
| WO2025247829A1 (en) | 2024-05-27 | 2025-12-04 | Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for treating prostate cancer |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| FI903489A0 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna. |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| CA2102511A1 (en) | 1991-05-14 | 1992-11-15 | Paul J. Higgins | Heteroconjugate antibodies for treatment of hiv infection |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
| ATE181571T1 (de) | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
| CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
| DE69329503T2 (de) | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ES2332893T3 (es) | 1996-08-30 | 2010-02-15 | Upfront Chromatography A/S | Aislamiento de inmunoglobulinas. |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| US20080318254A9 (en) | 1997-03-10 | 2008-12-25 | The Regents Of The University Of California | PSCA antibodies and hybridomas producing them |
| US20020173629A1 (en) | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| EP1034298B1 (en) | 1997-12-05 | 2011-11-02 | The Scripps Research Institute | Humanization of murine antibody |
| CA2368734C (en) | 1999-03-30 | 2005-08-23 | Japan Tobacco Inc. | Method for preparing monoclonal antibody |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| AU2002243228B2 (en) * | 2000-11-16 | 2007-08-02 | The Regents Of The University Of California | Marine actinomycete taxon for drug and fermentation product discovery |
| CA2447114A1 (en) | 2001-05-16 | 2002-11-21 | Abgenix, Inc. | Human antipneumococcal antibodies from non-human animals |
| DK1425389T3 (da) | 2001-08-23 | 2012-01-30 | Genmab As | Interleukin-15-(IL-15)-specifikke humane antistoffer |
| CN1761482A (zh) | 2003-01-17 | 2006-04-19 | 纽约州立大学研究基金会 | 与胰腺癌相关的抗原、针对它的抗体以及诊断和治疗方法 |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| AU2004270103B2 (en) | 2003-05-21 | 2012-02-23 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies against Bacillusanthracis protective antigen |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| TW202442680A (zh) | 2008-12-09 | 2024-11-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| AU2011274363A1 (en) * | 2010-07-02 | 2013-01-24 | Medimmune, Llc | Antibody formulations |
| MX2013013054A (es) | 2011-05-12 | 2014-02-20 | Genentech Inc | Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura. |
| TWI835048B (zh) * | 2011-08-01 | 2024-03-11 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
| MX349096B (es) * | 2011-11-28 | 2017-07-11 | Merck Patent Gmbh | Anticuerpos anti-pd-l1 y sus usos. |
| CA3111357A1 (en) * | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| BR112015028326A8 (pt) | 2013-06-03 | 2018-01-23 | Novartis Ag | combinações de anticorpo anti-pd-l1, inibidor de mek e/ou inibidor de braf, seus kits e seus usos, e composição farmacêutica |
| EP4285928A3 (en) | 2013-09-27 | 2024-03-13 | F. Hoffmann-La Roche AG | Anti-pdl1 antibody formulations |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
-
2014
- 2014-09-26 EP EP23194749.0A patent/EP4285928A3/en not_active Withdrawn
- 2014-09-26 EA EA201690667A patent/EA033817B1/ru not_active IP Right Cessation
- 2014-09-26 BR BR112016006397-0A patent/BR112016006397B1/pt active IP Right Grant
- 2014-09-26 EP EP14784169.6A patent/EP3049441B1/en active Active
- 2014-09-26 SG SG10201708542RA patent/SG10201708542RA/en unknown
- 2014-09-26 WO PCT/US2014/057821 patent/WO2015048520A1/en not_active Ceased
- 2014-09-26 RS RS20200089A patent/RS59880B1/sr unknown
- 2014-09-26 PL PL14784169T patent/PL3049441T3/pl unknown
- 2014-09-26 MX MX2016003939A patent/MX375378B/es active IP Right Grant
- 2014-09-26 TW TW103133659A patent/TWI660738B/zh active
- 2014-09-26 AU AU2014324703A patent/AU2014324703C1/en active Active
- 2014-09-26 LT LTEP14784169.6T patent/LT3049441T/lt unknown
- 2014-09-26 CN CN201480064099.XA patent/CN105793288B/zh active Active
- 2014-09-26 UA UAA201604644A patent/UA122478C2/uk unknown
- 2014-09-26 HR HRP20200102TT patent/HRP20200102T1/hr unknown
- 2014-09-26 NZ NZ719036A patent/NZ719036A/en unknown
- 2014-09-26 MY MYPI2016000534A patent/MY175472A/en unknown
- 2014-09-26 SI SI201431471T patent/SI3049441T1/sl unknown
- 2014-09-26 HU HUE14784169A patent/HUE047194T2/hu unknown
- 2014-09-26 SG SG11201602283UA patent/SG11201602283UA/en unknown
- 2014-09-26 KR KR1020167010636A patent/KR102331663B1/ko active Active
- 2014-09-26 PE PE2016000416A patent/PE20160541A1/es unknown
- 2014-09-26 MA MA38960A patent/MA38960A1/fr unknown
- 2014-09-26 CA CA2925310A patent/CA2925310C/en active Active
- 2014-09-26 TW TW108108366A patent/TWI714022B/zh active
- 2014-09-26 JP JP2016517363A patent/JP6942465B2/ja active Active
- 2014-09-26 DK DK14784169.6T patent/DK3049441T3/da active
- 2014-09-26 PT PT147841696T patent/PT3049441T/pt unknown
- 2014-09-26 AR ARP140103581A patent/AR097791A1/es not_active Application Discontinuation
- 2014-09-26 ES ES14784169T patent/ES2768614T3/es active Active
- 2014-09-26 EA EA201991715A patent/EA201991715A1/ru unknown
- 2014-09-26 EP EP19199570.3A patent/EP3626742A1/en not_active Withdrawn
-
2016
- 2016-03-22 IL IL244712A patent/IL244712B/en active IP Right Grant
- 2016-03-23 MX MX2022014781A patent/MX2022014781A/es unknown
- 2016-03-23 MX MX2020010026A patent/MX2020010026A/es unknown
- 2016-03-23 CL CL2016000680A patent/CL2016000680A1/es unknown
- 2016-03-25 US US15/081,785 patent/US10875922B2/en active Active
- 2016-03-28 PH PH12016500566A patent/PH12016500566A1/en unknown
- 2016-03-29 CR CR20160141A patent/CR20160141A/es unknown
-
2019
- 2019-06-05 JP JP2019104978A patent/JP2019194195A/ja not_active Withdrawn
- 2019-08-20 PH PH12019501931A patent/PH12019501931A1/en unknown
- 2019-10-24 IL IL270165A patent/IL270165B/en unknown
-
2020
- 2020-05-19 AU AU2020203267A patent/AU2020203267B2/en active Active
- 2020-11-23 US US17/101,966 patent/US20210221892A1/en not_active Abandoned
-
2021
- 2021-06-29 JP JP2021107154A patent/JP2021169458A/ja not_active Withdrawn
- 2021-08-09 IL IL285474A patent/IL285474A/en unknown
-
2022
- 2022-09-23 AU AU2022235627A patent/AU2022235627A1/en active Pending
-
2023
- 2023-08-02 US US18/364,312 patent/US20240010732A1/en not_active Abandoned
- 2023-09-06 AR ARP230102359A patent/AR130402A2/es unknown
-
2024
- 2024-09-27 US US18/900,229 patent/US20250145717A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38960A1 (fr) | Formulations d'anticorps anti-pdl1 | |
| MX388893B (es) | Formulaciones de anticuerpos estables acuosas. | |
| MA47664B1 (fr) | Anticorps anti-c10orf54 et leurs utilisations | |
| MA43187A (fr) | Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations | |
| MA44637B1 (fr) | Composes hétérocycliques et leurs utilisations | |
| MA49043A (fr) | Formulation stable d'anticorps | |
| MA37538A2 (fr) | Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation | |
| MA40938A (fr) | Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps | |
| MA38686A1 (fr) | Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés | |
| EP2569330A4 (en) | CHLOROTOXIN VARIANTS AND CONJUGATES AND METHOD OF USE THEREOF | |
| MA38273A1 (fr) | Thérapie de combinaison avec des anticorps anti-her3 | |
| BR112015000520A2 (pt) | agente de espessamento estável com lipase | |
| EP2968553A4 (en) | ANTIBODY FORMULATIONS | |
| MA44550B1 (fr) | Anticorps anti-acide téichoique de la paroi cellulaire et conjugués associés | |
| MA49977A (fr) | Combinaisons pharmaceutiques comprenant un anticorps anti-ly75 | |
| MX2016005395A (es) | Formulacion estable de insulina glulisina. | |
| MA49947A (fr) | Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes | |
| EP4037711A4 (en) | COMPOSITIONS AND METHODS USING ANTI-NRP2 ANTIBODIES | |
| EA201591717A1 (ru) | Твердые формы гидрохлорида вемурафениба | |
| MA34709B1 (fr) | Compositions pharmaceutiques | |
| MA38492A1 (fr) | Anticorps et immunoconjugués anti-b7-h4 | |
| MA35947B1 (fr) | Anticorps et immunoconjugués anti-lgr5 | |
| TR201203085A2 (tr) | Sefetamet ve klavulanik asit içeren bileşimler. | |
| MA39141A1 (fr) | Anticorps anti-tau(ps422) humanisés et leurs méthodes d'utilisation | |
| MA38426B1 (fr) | Compositions antibiotiques de ceftolozane |